Prevalence and treatment of hypercholesterolaemia in patients with manifest vascular disease according to the criteria of the current cholesterol consensus;Prevalentie en behandeling van hypercholesterolemie bij patienten met manifest vaatlijden volgens de maatstaven van de huidige cholesterolconsensus

Nederlands Tijdschrift voor Geneeskunde

Volumn 144, Issue 15, 2000, Pages 706-709

  Van De Laak, M F ^b   Van Der Graaf, Y ^b   Banga, J D ^a   Simons, P C G ^b   Algra, A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; PREVALENCE; PROSPECTIVE STUDIES;

EID: 0034621051     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N End J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339: 1349-57.
5. Simoons ML, Casparie AF. Behandeling en preventie van coronaire hartzickten door verlaging van de serumcholesterolconcentratie; derde consensus 'Cholesterol'. Ned Tijdschr Geneeskd 1998;142: 2096-101.
6. Simons PCG, Algra A, Laak MF van de, Grobbee DE, Graaf Y van der. Second manifestations of arterial disease (SMART) study. Rationale and design. SMART Study Group. Eur J Epidemiol 1999; 15:773-81.
7. Simons PCG. Second manifestations of arterial disease. The SMART study [proefschrift]. Utrecht: Universiteit Utrecht; 1999.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
9. Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprolein(a), and apolipoproteins A-I and B. Clin Chem 1994; 40:574-8.
10. EUROASPIRE Study Group. European Action on Secondary-Prevention through Intervention to Reduce Events. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-82.
11. Nieto FJ, Alonso J, Chambless LE, Zhong M, Ceraso M, Romm FJ, et al. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities study. Arch Intern Med 1995;155:677-84.
12. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-6.
13. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of to years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
14. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997;131:1-5.
15. Laakso M, Pyörälä K, Voutilainen E, Marniemi J. Plasma insulin and serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetic and non-diabetic subjects. Am J Epidemiol 1987; 125:611-21.
16. O'Brien E, Bouchier-Hayes D, Fitzgerald D, Atkins N. The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic. Lancet 1998;352:1700-2.